Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.

Highlights,Bristol-Myers Squibb has seen adjustments in institutional holdings, reflecting shifts in market ...

Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...

Mary-Claire King, a groundbreaking innovator in genetics, received The National Academy of Sciences' most prestigious metal.

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, two months after the U.S. health regulator restricted imports from one of the drugmaker's key plants in India.

Oppenheimer & Co. Inc. reduced its stake in Bristol-Myers Squibb by 8.1%, selling nearly 19,000 shares in Q4. The ...

One of the lowest paid CEOs in pharma—and the only woman leading a top-tier giant—is set to receive up to $27.2 million in ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity ...

Major indices closed lower on Thursday following earnings from AI-darling Nvidia overnight and an update from Donald Trump ...